Revolution Medicines price target raised to $265
Benzinga reported that B of A Securities raised its price target on Revolution Medicines to $265.00 per share from $225.00.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
UBS raises Revolution Medicines price target to $265
UBS raised its Revolution Medicines price target to $265.00 per share from $220.00.